Varex Q2 Earnings: A Bellwether for Health and Security Tech

SALT LAKE CITY, UT – April 22, 2026 – Varex Imaging Corporation (Nasdaq: VREX) is set to become a focal point for the technology and investment communities as it prepares to release its unaudited second-quarter financial results for fiscal year 2026. The announcement, scheduled for after the market closes on Thursday, May 7, 2026, will be followed by a conference call where executives will detail the company's performance. Investors and industry analysts are watching closely, as the results will provide a critical pulse check on the health of the global X-ray imaging market and Varex's ability to capitalize on key trends in medicine, security, and industry.

The upcoming report follows a period of strong performance and positive investor sentiment. The company has consistently surpassed analyst expectations in recent quarters, buoyed by robust growth in its industrial segment and steady progress in its core medical business. The Q2 figures will be scrutinized for signs of sustained momentum and will offer insights into how the company is navigating a complex landscape of technological innovation and competitive pressure.

Recapping a Strong Start to Fiscal 2026

Varex entered its second quarter on solid footing, having reported impressive results for Q1 FY2026. The company posted revenues of $210 million, a 5% year-over-year increase that landed at the high end of its own guidance. More significantly for investors, non-GAAP diluted earnings per share (EPS) came in at $0.19, smashing analyst consensus estimates of $0.14 by nearly 36%. The positive surprise triggered a 1.85% jump in aftermarket trading, pushing the stock near its 52-week high and signaling strong market confidence.

A key highlight of the company’s recent financial health has been its disciplined approach to debt management. Varex significantly reduced its total debt from $567 million in the first quarter of 2025 to $368 million in the first quarter of 2026. This deleveraging improved its net debt leverage ratio from 2.4x to 1.9x, a metric that provides investors with greater assurance of the company's financial stability and flexibility. While the company did report a negative cash flow from operations, attributed to seasonal factors and inventory build-up, the substantial reduction in debt remains a powerful positive indicator.

Industrial Segment Shines Amid Global Security Demands

While the medical segment remains Varex's largest revenue source, the Industrial division has become the primary engine of growth. In the first quarter, the segment’s revenue surged by 17% year-over-year, a trend driven largely by high demand for cargo security systems. This performance aligns perfectly with broader market dynamics.

The global X-ray security screening market is experiencing a significant boom, with projections estimating the industry will reach a value of $4.54 billion in 2026 and grow at a compound annual growth rate (CAGR) of 9.2% through 2035 to surpass $10.1 billion. This expansion is fueled by heightened global security concerns, increased investment in airport and port infrastructure, and a concerted effort to combat illegal trade and terrorism. X-ray systems, known for their reliability and versatility, are expected to maintain their dominant 26.1% market share in the security screening sector in 2026.

Varex is well-positioned to continue benefiting from this trend. Management commentary in previous quarters has consistently highlighted momentum in the cargo security business, and investors will be looking for confirmation in the Q2 report that this high-margin growth is sustainable.

Navigating the Evolving Medical Imaging Landscape

The medical segment, which accounts for the majority of Varex’s revenue, is navigating a landscape of profound technological change. While revenue in this segment remained stable at $145 million in the first quarter, the company is actively investing in next-generation technologies to secure future growth. One of the most promising initiatives is in photon-counting CT technology, a revolutionary approach that promises higher-resolution images at lower radiation doses.

This focus on innovation is critical as the medical imaging industry embraces artificial intelligence. A major trend in 2026 is the rise of "edge AI," where algorithms run directly on imaging devices for faster analysis. Furthermore, the market is seeing a push toward multimodal decision-support systems that integrate imaging data with other patient information for more holistic diagnostics. Varex’s role as a component supplier to major original equipment manufacturers (OEMs) places it at the center of these advancements.

In past discussions, CEO Sunny Sanyal has emphasized the company’s strategic focus on securing design wins and expanding its product line for mid-tier and value-tier CT systems, a significant global market. The Q2 report may provide an update on progress in these key growth initiatives, which are vital for long-term competitiveness.

Investor Outlook and Competitive Pressures

For the upcoming announcement, Varex has guided for Q2 revenues between $210 million and $225 million, with non-GAAP EPS projected to be between $0.15 and $0.25. Meeting or exceeding the higher end of this range will be crucial for maintaining the stock's upward trajectory. Investors will be parsing the results to see if the industrial segment can repeat its stellar performance and if medical segment sales show renewed strength.

However, Varex operates in a fiercely competitive environment. It contends not only with direct rivals in digital detectors like Canon and Trixell but also with its own major customers—integrated giants like Siemens Healthineers, GE Healthcare, and Philips, which also produce components in-house. Varex’s strength lies in its independence and its vast portfolio of over 800 patents, which create significant barriers to entry. As the world's largest independent manufacturer of X-ray tubes, with an estimated 35% global market share, its position is formidable but requires constant innovation.

As the May 7th conference call approaches, the key questions are clear. Can Varex continue its streak of beating expectations? Will the industrial segment's explosive growth continue to offset more modest gains in the medical field? And what will management's guidance for the third quarter reveal about the outlook for the remainder of fiscal year 2026? The answers will not only determine the next move for VREX stock but will also offer a valuable window into the future of imaging technology itself.